Norovirus Gastroenteritis
Gastroenterology
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Vaccine
1100%
+ 1 programs with unclassified modality
Competitive Landscape
1 companies ranked by most advanced pipeline stage
VaxartSOUTH SAN FRANCISCO, CA
2 programs2
VXA-G1.1-NNPhase 11 trial
VXA-G1.1-NN Oral VaccinePhase 1Vaccine1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
VaxartVXA-G1.1-NN Oral Vaccine
VaxartVXA-G1.1-NN
Clinical Trials (2)
Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers
Start: Apr 2017Est. completion: May 2018
Phase 1Completed
Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine
Start: Jul 2016Est. completion: Oct 2017
Phase 1Completed
Related Jobs in Gastroenterology
Specialty Representative, Gastroenterology – Minneapolis, Minnesota
AbbVie
Remote
11h ago
Head of Drug Product Development
Ironwood Pharmaceuticals
Boston, Massachusetts, United States
12h ago
$246K - $287K/yr
Regulatory Affairs Associate
Ferring Pharmaceuticals
Istanbul, Turkey
Yesterday
Key Account Director, Diagnostics and Research
Tempus
Remote
Yesterday
$150K - $200K/yr
Senior Sterilization Validation Engineer (m/f/d)
Johnson & Johnson
Beerse, Antwerp, Belgium
Yesterday
Senior Financial Analyst - Supply Chain Finance & Transformation (m/f/d)
Johnson & Johnson
Norderstedt, Schleswig-Holstein, Germany
Yesterday
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space